[1] |
马沙沙, 高春明. PC、SD、PC/SD、FIB-4对肝硬化食管静脉曲张的诊断价值[J]. 蚌埠医学院学报, 2020, 45(10): 1344. doi: 10.13898/j.cnki.issn.1000-2200.2020.10.008 |
[2] |
左怀文, 沙启梅, 孙姣, 等. 肝硬化食管静脉曲张患者门静脉血栓形成的危险因素分析[J]. 临床肝胆病杂志, 2021, 37(1): 63. doi: 10.3969/j.issn.1001-5256.2021.01.013 |
[3] |
LIM J, KIM H I, KIM E, et al. Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study[J]. BMC Cancer, 2021, 21(1): 11. doi: 10.1186/s12885-020-07708-1 |
[4] |
ZANETTO A, GARCIA-TSAO G. Some Answers and more questions about portal vein thrombosis in patients with decompensated cirrhosis[J]. Clin Gastroenterol Hepatol, 2020, 18(11): 2432. doi: 10.1016/j.cgh.2020.04.004 |
[5] |
中华医学会肝病学分会. 肝硬化诊治指南[J]. 中华肝脏病杂志, 2019, 27(11): 846. doi: 10.3760/cma.j.issn.1007-3418.2019.11.008 |
[6] |
中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会消化内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 中华内科杂志, 2016, 55(1): 57. doi: 10.3760/cma.j.issn.0578-1426.2016.01.015 |
[7] |
黄鹤, 伦伟健, 梁晓燕, 等. 肝硬化食管胃静脉曲张破裂出血相关危险因素分析[J]. 四川医学, 2016, 37(3): 320. doi: 10.16252/j.cnki.issn1004-0501-2016.03.027 |
[8] |
黄晓铨, 倪礼爰, 姜思雨, 等. 门静脉血栓影响内镜治疗预防乙型肝炎肝硬化食管胃静脉曲张破裂再出血的疗效[J]. 中华肝脏病杂志, 2020, 28(9): 747. doi: 10.3760/cma.j.cn501113-20200616-00326 |
[9] |
肖春桃, 李贤秋, 周贤. 肝硬化门静脉血栓形成的危险因素分析[J]. 中国临床研究, 2021, 34(3): 341. doi: 10.13429/j.cnki.cjcr.2021.03.012 |
[10] |
NORTHUP PG, GARCIA-PAGAN JC, GARCIA-TSAO G, et al. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2021, 73(1): 366. doi: 10.1002/hep.31646 |
[11] |
杨静. 肝硬化患者食管胃静脉曲张破裂出血后门静脉血栓形成的危险因素分析[D]. 太原: 山西医科大学, 2021. |
[12] |
YUAN J, XU GM. Early and late stent thrombosis in patients with versus without diabetes mellitus following percutaneous coronary intervention with drug-eluting stents: a systematic review and Meta-analysis[J]. Am J Cardiovasc Drugs, 2018, 18(6): 483. doi: 10.1007/s40256-018-0295-y |
[13] |
BORJAS-ALMAGUER OD, CORTEZ-HERNANDEZ CA, GONZALEZ-MORENO EI, et al. Portal vein thrombosis in patients with cirrhosis: just a common finding or a predictor of poor outcome?[J]. Ann Hepatol, 2016, 15(6): 902. |
[14] |
AMITRANO L, GUARDASCIONE MA, BRANCACCIO V, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis[J]. J Hepatol, 2004, 40(5): 736. doi: 10.1016/j.jhep.2004.01.001 |
[15] |
DONG G, HUANG XQ, ZHU YL, et al. Increased portal vein diameter is predictive of portal vein thrombosis development in patients with liver cirrhosis[J]. Ann Transl Medicine, 2021, 9(4): 289 doi: 10.21037/atm-20-4912 |
[16] |
ABD-ELSALAM S, HABBA E, ELKHALAWANY W, et al. Correlation of platelets count with endoscopic findings in a cohort of Egyptian patients with liver cirrhosis[J]. Medicine, 2016, 95(23): e3853. doi: 10.1097/MD.0000000000003853 |
[17] |
韩晶, 毛锦娟, 吴时胜, 等. 肝硬化上消化道出血患者并发门静脉血栓形成的危险因素[J]. 中华实用诊断与治疗杂志, 2018, 32(6): 571. |
[18] |
曾钗明, 郭太林, 陈建康, 等. 肝硬化联合门静脉血栓形成的危险因素及预后效果[J]. 血管与腔内血管外科杂志, 2019, 5(5): 407. doi: 10.19418/j.cnki.issn2096-0646.2019.05.004 |
[19] |
MALAGUARNERE M, LATTERI S, BERTINO G, et al. D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosis[J]. Clin Exp Gastroenterol, 2018, 11(3): 373. |
[20] |
RIVA N, VELLA K, HICKEY K, et al. Biomarkers for the diagnosis of venous thromboembolism: D-dimer, thrombin generation, procoagulant phospholipid and soluble P-selectin[J]. J Clin Pathol, 2018, 71(11): 1015. doi: 10.1136/jclinpath-2018-205293 |
[21] |
梅勇, 周志林, 杨旭辉, 等. P-选择素和D-二聚体对肝硬化门静脉血栓形成的早期预测作用研究[J]. 现代消化及介入诊疗, 2020, 25(9): 1231. doi: 10.3969/j.issn.1672-2159.2020.09.023 |
[22] |
JUN J, XING G, WANG H, et al. Association between metabolic abnormalities and HBV related hepatocelluar carcinoma in Chinese: a cross-sectional study[J]. Nutr J, 2011, 10(1): 49. |
[23] |
李巍, 王莉莉, 李海燕, 等. 急性缺血性卒中患者无症状深静脉血栓形成危险因素分析[J]. 中国现代神经疾病杂志, 2021, 21(7): 592. doi: 10.3969/j.issn.1672-6731.2021.07.011 |
[24] |
OKANO K, SHITAMOTO K, ARAKI M, et al. Influencing factors in quantitative measurement using activated platelet levels and platelet-activating capacity for the assessment of thrombosis in pre-metabolic syndrome and type 2 diabetes mellitus[J]. Nurs Health Sci, 2018, 20(1): 69. doi: 10.1111/nhs.12389 |